Mitiglinide calcium hydrate

Research use only, not for human use.

An insulin secretion stimulator by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

An insulin secretion stimulator by closing the ATP-sensitive potassium KATP channels in pancreatic β cells; has potent hypoglycemic effects.Diabetes Approved(In Vitro):Mitiglinide calcium hydrate inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells.(In Vivo):Mitiglinide Calcium hydrate (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load.

Mitiglinide calcium hydrate inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells.

Mitiglinide Calcium hydrate (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load. Animal Model:Pregnant Wistar rats (12 weeks)Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration:Oral administration Result:Dose-dependently suppressed AUCglucose levels.

KAD-1229 calcium hydrate | S-21403 calcium hydrate

Cell Cycle/DNA Damage

Potassium Channel

PotassiumChannel

Metabolic Disease

Diabetes

207844-01-7

353.46

C19H25NO3 . 1/2 Ca . H2O

>98% (HPLC)

10 mM in DMSO

C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)[O-].C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)[O-].O.O.[Ca+2]

2H-Isoindole-2-butanoic acid, octahydro-γ-oxo-α-(phenylmethyl)-, calcium salt, hydrate (2:1:2), (αS,3aR,7aS)-

(-20℃)

With Ice Pack

≥ 2 years